Literature DB >> 32485206

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Kerstin Stemmer1, Brian Finan2, Richard D DiMarchi3, Matthias H Tschöp4, Timo D Müller5.   

Abstract

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Diabetes; Dyslipidemia; Incretins; Lipoproteins; Obesity

Year:  2020        PMID： 32485206     DOI： 10.1016/j.addr.2020.05.008

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN： 0169-409X            Impact factor:   15.470


  5 in total

1.  The potential mechanism of Liu-Wei-Di-Huang Pills in treatment of type 2 diabetic mellitus: from gut microbiota to short-chain fatty acids metabolism.

Authors:  Zi-Yang Yi; Lin Chen; Yan Wang; Dan He; Di Zhao; Shui-Han Zhang; Rong Yu; Jian-Hua Huang
Journal:  Acta Diabetol       Date:  2022-07-20       Impact factor: 4.087

Review 2.  The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.

Authors:  Zengguang Kuang; Ningning Hou; Chengxia Kan; Fang Han; Hongyan Qiu; Xiaodong Sun
Journal:  Int Urol Nephrol       Date:  2022-08-29       Impact factor: 2.266

Review 3.  Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Authors:  Jan Borén; Marja-Riitta Taskinen; Elias Björnson; Chris J Packard
Journal:  Nat Rev Cardiol       Date:  2022-03-22       Impact factor: 49.421

4.  Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.

Authors:  Fenghui Zhao; Qingtong Zhou; Zhaotong Cong; Kaini Hang; Xinyu Zou; Chao Zhang; Yan Chen; Antao Dai; Anyi Liang; Qianqian Ming; Mu Wang; Li-Nan Chen; Peiyu Xu; Rulve Chang; Wenbo Feng; Tian Xia; Yan Zhang; Beili Wu; Dehua Yang; Lihua Zhao; H Eric Xu; Ming-Wei Wang
Journal:  Nat Commun       Date:  2022-02-25       Impact factor: 14.919

5.  Saponins from Camellia sinensis Seeds Stimulate GIP Secretion in Mice and STC-1 Cells via SGLT1 and TGR5.

Authors:  Huanqing Zhu; Kaixi Wang; Shuna Chen; Jiaxin Kang; Na Guo; Hongbo Chen; Junsheng Liu; Yuanyuan Wu; Puming He; Youying Tu; Bo Li
Journal:  Nutrients       Date:  2022-08-19       Impact factor: 6.706
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.